Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (666,704,000)	$ (311,656,000)	$ (217,490,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23,227,000	32,071,000	23,699,000
Amortization and impairment of internal-use software	6,255,000	4,427,000	2,449,000
Stock-based compensation expense	120,209,000	116,017,000	57,933,000
Changes in fair value of warrant liabilities	0	0	(32,989,000)
Impairment of long-lived assets	0	10,126,000	0
Goodwill impairment	351,744,000	0	0
Loss on disposition of Lemonaid Health Limited	2,026,000	0	0
Other operating activities	(529,000)	77,000	85,000
Changes in operating assets and liabilities:
Accounts receivable, net	(1,427,000)	1,483,000	(899,000)
Inventories	(2,218,000)	542,000	(4,262,000)
Deferred cost of revenue	584,000	2,325,000	(2,219,000)
Prepaid expenses and other current assets	(1,231,000)	6,653,000	(10,077,000)
Operating lease right-of-use assets	7,185,000	7,393,000	7,078,000
Other assets	1,152,000	(429,000)	(1,820,000)
Accounts payable (includes related party amounts of $623, $(9,381) and $8,145, respectively)	(996,000)	(24,573,000)	22,856,000
Accrued expenses and other current liabilities (includes related party amounts of $(1,986), $2,966 and $(1,293), respectively)	(7,104,000)	2,671,000	8,316,000
Deferred revenue (includes related party amounts of $9,246, $2,572 and $(20,959), respectively)	12,307,000	(418,000)	(8,799,000)
Operating lease liabilities	(8,790,000)	(8,934,000)	(7,054,000)
Other liabilities	(9,000)	(3,165,000)	(3,635,000)
Net cash used in operating activities	(164,319,000)	(165,390,000)	(166,828,000)
Cash flows from investing activities:
Purchases of property and equipment	(1,129,000)	(4,048,000)	(3,968,000)
Proceeds from sale of property and equipment	30,000	5,000	1,000
Purchases of intangible assets	0	0	(5,500,000)
Capitalized internal-use software costs	(8,527,000)	(7,262,000)	(4,505,000)
Cash paid for acquisitions, net of cash acquired	0	0	(94,165,000)
Net cash used in investing activities	(9,626,000)	(11,305,000)	(108,137,000)
Cash flows from financing activities:
Proceeds from exercise of stock options	909,000	4,203,000	16,998,000
Proceeds from issuance of common stock under employee stock purchase plan	3,262,000	6,464,000	0
Payments for taxes related to net share settlement of equity awards	(230,000)	(197,000)	0
Payments of deferred offering costs	(357,000)	(693,000)	(30,642,000)
Proceeds from issuance of common stock upon merger	0	0	309,720,000
Proceeds from PIPE (includes related party amounts of nil, nil and $25,000, respectively)	0	0	250,000,000
Proceeds from exercise of merger warrants	0	0	44,000
Payment for warrant redemptions	0	0	(116,000)
Net cash provided by financing activities	3,584,000	9,777,000	546,004,000
Effect of exchange rates on cash and cash equivalents	0	385,000	(146,000)
Net (decrease) increase in cash, cash equivalents and restricted cash	(170,361,000)	(166,533,000)	270,893,000
Cash, cash equivalents and restricted cash — beginning of period	395,222,000	561,755,000	290,862,000
Cash, cash equivalents and restricted cash — end of period	224,861,000	395,222,000	561,755,000
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	97,000	473,000	722,000
Stock-based compensation capitalized for internal-use software costs	3,606,000	3,191,000	1,166,000
Reclassification of deferred offering costs	0	0	3,971,000
Assumption of merger warrants liability	0	0	75,415,000
Deferred offering costs during the period included in accounts payable and accrued expenses	1,000	45,000	0
Conversion of redeemable convertible preferred stock to common stock	0	0	837,351,000
Redemption/exercise of Class A common stock warrants	0	0	42,354,000
Stock consideration in acquisition of businesses, including fair value of common stock issued and stock-based awards that were vested	0	0	322,842,000
Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown in the consolidated statements of cash flows above:
Cash and cash equivalents	216,488,000	386,849,000	553,182,000
Restricted cash, current	1,399,000	1,399,000	1,599,000
Restricted cash, noncurrent	6,974,000	6,974,000	6,974,000
Total cash, cash equivalents and restricted cash	$ 224,861,000	$ 395,222,000	$ 561,755,000